Unite d'Hemostase Clinique, Hopital Edouard Herriot, Lyon, France.
Thromb Res. 2012 Dec;130(6):929-34. doi: 10.1016/j.thromres.2012.07.017. Epub 2012 Aug 19.
The thrombin generation test (TGT) has demonstrated utility in evaluating overall hemostatic capacity both in bleeding and thrombotic disorders. Although the test is currently well accepted as a research tool, its role in clinical practice has not yet been defined through large prospective multicenter clinical studies. Such prospective studies have been limited by the lack of official standardization of the assay and its large inter-laboratory variability. This international study assessed the intra- and inter-assay imprecision of TGT as well as the inter-centre variability of results in one US and four European centres. Contact-inhibited plasmas from six healthy volunteers, one mild haemophilia A patient, and five patients with heterozygous prothrombin G20210 mutation were assayed. We demonstrated that, using identical equipement, standardized reagents, a carefully selected reference plasma for normalization of results and the same test procedure as described in our DVD, the assay variability was highly reduced compared to previously published data. Our results emphasize the importance of preheating on TGT results and the variability of the assay. In conclusion, our data demonstrated that the standardized TGT methodology evaluated in this study effectively reduces the variability of the assay to acceptable limits and may be used in clinical trials.
凝血酶生成试验(TGT)已被证明可用于评估出血和血栓性疾病中的整体止血能力。尽管该试验目前被广泛接受为研究工具,但尚未通过大型前瞻性多中心临床研究来确定其在临床实践中的作用。这种前瞻性研究受到缺乏正式的检测标准化和其在实验室间的巨大变异性的限制。这项国际研究评估了 TGT 的室内和室间精密度以及在美国一个中心和欧洲四个中心的结果的中心间变异性。使用相同的设备、标准化试剂、精心选择的参考血浆来标准化结果以及与我们的 DVD 中描述的相同的测试程序,对来自六个健康志愿者、一个轻度血友病 A 患者和五个杂合子凝血酶原 G20210 突变患者的接触抑制血浆进行了检测。我们证明,与之前发表的数据相比,使用相同的设备、标准化试剂、精心选择的参考血浆来标准化结果以及与我们的 DVD 中描述的相同的测试程序,该检测的变异性显著降低。我们的结果强调了 TGT 结果预热的重要性和检测的变异性。总之,我们的数据表明,本研究中评估的标准化 TGT 方法有效地将检测的变异性降低到可接受的限度内,可用于临床试验。